192 related articles for article (PubMed ID: 18540333)
1. [Valsartan improves symptoms and quality of life in patients with chronic heart failure].
Baumhäkel M; Müller U; Böhm M
MMW Fortschr Med; 2008 Apr; 150 Suppl 1():48-53. PubMed ID: 18540333
[TBL] [Abstract][Full Text] [Related]
2. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
4. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
5. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
6. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
7. [New effective dosage of valsartan. High dosage--effective against high blood pressure].
MMW Fortschr Med; 2007 Nov; 149(46):52-3. PubMed ID: 18069195
[No Abstract] [Full Text] [Related]
8. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
[TBL] [Abstract][Full Text] [Related]
9. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
10. [Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
Shvetsov MIu; Medvedeva TIu; Kozlovskaia NL; Miroshnichenko NG; Okonova EB; Shonichev DG; Rudenko TE; Stavrovskaia EV; Plieva OK
Ter Arkh; 2001; 73(6):55-61. PubMed ID: 11521525
[TBL] [Abstract][Full Text] [Related]
11. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
Krum H; Carson P; Farsang C; Maggioni AP; Glazer RD; Aknay N; Chiang YT; Cohn JN
Eur J Heart Fail; 2004 Dec; 6(7):937-45. PubMed ID: 15556056
[TBL] [Abstract][Full Text] [Related]
12. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
[TBL] [Abstract][Full Text] [Related]
13. [Tolerance to valsartan in office practice in 3,197 hypertensive patients (the VALSE study)].
Ghannad E; Francillon A; Vaillant J; Bourdeix I; Gosse P
Ann Cardiol Angeiol (Paris); 2000 Feb; 49(1):13-20. PubMed ID: 12555316
[TBL] [Abstract][Full Text] [Related]
14. [Valsartan improves symptoms and quality of life in patients with chronic heart failure].
Baumhäkel M; Müller U
MMW Fortschr Med; 2008 Dec; 150(49-50):55. PubMed ID: 19133371
[No Abstract] [Full Text] [Related]
15. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
[TBL] [Abstract][Full Text] [Related]
17. The VALUE trial: a commentary.
Sever P
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):99-101. PubMed ID: 15526243
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
[TBL] [Abstract][Full Text] [Related]
19. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial.
van der Bom T; Winter MM; Bouma BJ; Groenink M; Vliegen HW; Pieper PG; van Dijk AP; Sieswerda GT; Roos-Hesselink JW; Zwinderman AH; Mulder BJ
Circulation; 2013 Jan; 127(3):322-30. PubMed ID: 23247302
[TBL] [Abstract][Full Text] [Related]
20. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
